"Morley Research Consortium is very excited to partner with Umthunzi”, said Jane Green, PhD, President and CEO of Morley Research Consortium. “With many Health IT companies’ software now coming under the FDA medical devices purview, this partnership provides an ideal combination of research and IT compliance for Morley’s CRO based clients as well as compliance assistance to hospitals and universities. We have been working closely with Umthunzi’s CEO Ramon Dempers and the entire Umthunzi team, and are impressed with their commitment to providing superior, innovative services to clinical research organizations.”
“We are excited about drawing together the extensive knowledge and experience of Morley with that of Umthunzi,” said Ramon Dempers, CEO of Umthunzi. “We are bringing world class products and services to the clinical research community in part though Morley’s experience and their broad sponsor base.” Key Umthunzi attributes benefitting the Clinical Research Organization (CRO) community are the development of breakthrough Pharmacovigilence and clinical research software, such as EDC solutions using Microsoft cloud technologies. Also, GXP, GAP analysis, Part 11 compliance and computer systems validation are critical to the overall success of clinical data and adverse event management.
Industry leaders understand that innovation of process, products and services is of paramount strategic importance in order to remain relevant. As a result of partnerships like MRC and Umthunzi, clinical research data collection has finally evolved to the 21st century. Like most industries, hard copy paper research work will soon be a part of the past with secure electronic capabilities that are here today, and with a future driven by the creative geniuses of those who continue to innovate. Morley Research Consortium and Umthunzi are two of those innovative organizations.
About Morley Research Consortium: Morley Research Consortium (MRC) is a Full Service CRO meeting the needs of the Medical Device, Pharmaceutical and BioTech research community. In addition to comprehensive clinical trial project management services for Phase I, Phase II, Phase III and Phase IV trials encompassing the earliest stages of protocol development through clinical trials and post-approval research, MRC provides contract management services for each aspect of the clinical trial contracting and management process. Their seasoned team of professionals have successfully managed clinical trials in a wide variety of therapeutic areas both nation wide and globally. Morley’s reputation for delivering FDA guideline Clinical Trials, on time and on budget, makes them the first choice for the clinical research community.
About Umthunzi: Based in Atlanta, GA and offices in Little Rock, AR, Umthunzi, is an innovative company providing a broad range of products and services to the Life Science community, with particular emphasis in Clinical Research. The company has been developing its products and services for over 7 years with an absolute focus on Life Science. The company provides outsource management services and local service to US companies wanting to conduct clinical trials globally. Additionally, they offer the company's best in class software products and services to facilitate clinical research and provide the tools needed for both Sponsors and Clinical Research Organizations (CRO). Their products are designed to allow companies to collaborate and communicate effectively, while ensuring the integrity of the data developed during the drug development life cycle. Umthunzi has an experienced and effective management team that brings a wide range of skills and expertise to every engagement and Client with whom they partner.
For Contact Information:
Jane Green, Ph.D.
Morley Research Consortium, LLC
1175 Grimes Bridge Rd., Suite 500
Roswell, GA 30075
Shawn B. Ironside
Director Clinical Operation
13010 Morris Road
Alpharetta, GA 30004
Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company’s products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.